Company Overview of Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company’s product pipeline includes VYXEOS, a nano-scale liposomal formulation of irinotecan:floxuridine, which is in Phase III clinical testing for the treatment of acute myeloid leukemia; CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and ...
200 PrincetonSouth Corporate Center
Ewing, NJ 08628
Founded in 1999
Key Executives for Celator Pharmaceuticals, Inc.
Chief Executive Officer and Director
Founder, President and Chief Scientific Officer
Chief Financial Officer and Vice President
Compensation as of Fiscal Year 2017.
Celator Pharmaceuticals, Inc. Key Developments
Celator Pharmaceuticals, Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM
May 27 17
Celator Pharmaceuticals, Inc. Presents at BIO International Conference 2017, Jun-21-2017 01:45 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Derek Miller, Chief Business Officer.
Celator Pharmaceuticals, Inc. Files Form 15
Jul 22 16
Celator Pharmaceuticals, Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of par value $0.001 per share under the Securities Exchange Act of 1934, as amended.
Celator Pharmaceuticals, Inc.(NasdaqGM:CPXX) dropped from NASDAQ Composite Index
Jul 13 16
Celator Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries